Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,844 Million (Mid Cap)
27.00
NA
1.34%
-0.23
6.61%
1.95
Revenue and Profits:
Net Sales:
356 Million
(Quarterly Results - Sep 2025)
Net Profit:
75 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.56%
0%
16.56%
6 Months
17.04%
0%
17.04%
1 Year
23.52%
0%
23.52%
2 Years
-7.55%
0%
-7.55%
3 Years
-23.45%
0%
-23.45%
4 Years
-66.54%
0%
-66.54%
5 Years
0%
0%
0.0%
Chengdu Kanghua Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.68%
EBIT Growth (5y)
-3.53%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.40
Tax Ratio
14.30%
Dividend Payout Ratio
33.03%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
28.87%
ROE (avg)
16.97%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
1.98
EV to EBIT
21.93
EV to EBITDA
17.60
EV to Capital Employed
2.24
EV to Sales
5.22
PEG Ratio
NA
Dividend Yield
1.35%
ROCE (Latest)
10.19%
ROE (Latest)
7.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
356.10
319.30
11.53%
Operating Profit (PBDIT) excl Other Income
92.50
118.30
-21.81%
Interest
0.80
1.30
-38.46%
Exceptional Items
0.00
7.00
-100.00%
Consolidate Net Profit
74.60
99.30
-24.87%
Operating Profit Margin (Excl OI)
259.80%
329.70%
-6.99%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 11.53% vs -10.21% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -24.87% vs -17.73% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,421.60
1,567.60
-9.31%
Operating Profit (PBDIT) excl Other Income
591.10
660.80
-10.55%
Interest
5.40
4.90
10.20%
Exceptional Items
-59.70
-31.90
-87.15%
Consolidate Net Profit
398.70
509.20
-21.70%
Operating Profit Margin (Excl OI)
363.30%
382.10%
-1.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -9.31% vs 8.97% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -21.70% vs -14.86% in Dec 2023
About Chengdu Kanghua Biological Products Co., Ltd. 
Chengdu Kanghua Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






